Preci

Preci and Biopredic International partner for higher performance of suspended pooled hepatocytes with extended longevity and large-scale availability

License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies 10 April 2024 -- Kyiv, Ukraine, and Rennes, France -- Preci, a biotechnology company advancing patient-derived cell models to bridge the gap between preclinical testing and clinical trials, and Biopredic International, a biotechnology company specialising...
Mykoly Amosova vulytsia 12, Kyiv, Kyivska 03038, Ukraine